ERCC1

Across TCGA pan-cancer cohorts, ERCC1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ERCC1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ERCC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERCC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and PRAD are the cancer types where ERCC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
UCEC	DFS	Median	All	1.000	0.619	.008	20	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
GBM	DFS	Median	All	0.060	0.242	.016	3	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ERCC1–OV (DFS)

Open the OV breakdown →